AASLD – The Liver Meeting 2018 Conference bulletinRead our 2018 Liver Meeting bulletin in English, Spanish, Russian, French & Portuguese. Tracey Simon at The Liver Meeting 2018. Photo by Liz Highleyman.Hepatocellular carcinomaAspirin use associated with lower risk of liver cancer. Kathleen Schwarz at The Liver Meeting 2018. Photo by Liz Highleyman.Treatment outcomesSofosbuvir/ledipasvir cures most young children with hepatitis C. infohep news NAFLD Experimental therapy improves liver health in people with fatty liver disease Liz Highleyman / 31 January 2019 NGM282, an experimental fibroblast growth factor analogue, reduced liver fat build-up and the development of scar tissue in people with non-alcoholic steatohepatitis, according to studies presented at the recent AASLD Liver Meeting in ... Antiviral therapy Tenofovir alafenamide for hepatitis B shows improved kidney and bone safety after a year Liz Highleyman / 08 January 2019 Tenofovir alafenamide (TAF; Vemlidy), the new formulation of tenofovir, continues to appear at least equally effective for treatment of hepatitis B but with a better safety profile than the older tenofovir disoproxil fumarate ... NAFLD Aramchol reduces liver fat in people with NASH Liz Highleyman / 02 January 2019 A novel type of experimental therapy led to a significant reduction in liver fat and improvement in liver health among people with non-alcoholic steatohepatitis (NASH), according to study presented at the recent AASLD Liver ... Antiviral therapy Hepatitis B capsid assembly modulators show good antiviral activity Liz Highleyman / 21 December 2018 Experimental drugs that interfere with hepatitis B virus (HBV) capsid assembly continue to show promise as a new approach to antiviral treatment, according to research presented at the AASLD Liver Meeting last ... NAFLD Lean people can develop fatty liver disease Liz Highleyman / 17 December 2018 Metabolically healthy lean people may develop non-alcoholic fatty liver disease (NAFLD), although this is much more common among people with obesity and metabolic abnormalities, according to research presented at the AASLD Liver ... Hepatitis C elimination Hepatitis C rates in US track the opioid epidemic Liz Highleyman / 14 December 2018 Nearly 2.4 million people in the United States are living with active hepatitis C virus (HCV) infection, according to the latest data from the US Centers for Disease Control and Prevention (CDC). ... NAFLD Thyroid hormone receptor agonists reduce liver fat in people with NAFLD Liz Highleyman / 29 November 2018 Thyroid hormone activation appears to be a promising approach for treating fatty liver disease, according to a pair of studies presented at the AASLD Liver Meeting this month in San Francisco. Two thyroid ... Hepatocellular carcinoma (HCC) Nivolumab works well for liver cancer patients with advanced disease Liz Highleyman / 26 November 2018 Nivolumab (Opdivo), a checkpoint inhibitor that helps the immune system fight cancer, was associated with tumour shrinkage or disease stabilisation in just over half of hepatocellular carcinoma (HCC) patients with substantial liver function ... Treatment for people who use drugs People who inject drugs have a high hepatitis C cure rate despite imperfect adherence Liz Highleyman / 15 November 2018 Most people who inject drugs completed treatment with sofosbuvir/velpatasvir (Epclusa) and achieved sustained virological response (SVR) in a real-world setting, even if they had interruptions in therapy, according to a presentation at the AASLD ... Pan-genotypic regimens 8 weeks of Maviret cures 98% of people with hepatitis C and cirrhosis Keith Alcorn / 14 November 2018 An 8-week course of the combination of glecaprevir and pibrentasvir (Maviret) is highly effective in curing hepatitis C in people with compensated cirrhosis, across a wide range of genotypes, Robert S. Brown of ... View more > Editors' picks from other sources Side effects Do Patients with Chronic Liver Disease Face Higher Drug-Induced Liver Injury Risk? MedPage Today / 14 November 2018 NAFLD Novel Thyroid Beta Receptor Agonist Cut LDL-C in NAFLD Patients MedPage Today Gastroenterology / 14 November 2018 Treatment outcomes DAA Treatment and Hepatic Fibrosis Improvement in HCV: What's the Link? Monthly Prescribing Reference / 14 November 2018 Screening and testing policy Universal HCV Screening on the Way? MedPage Today / 12 November 2018 Hepatocellular carcinoma (HCC) Five Years of Regular Aspirin Use Helps Prevent Common Liver Cancer AASLD press release / 12 November 2018 Deciding when and how to treat HCV Hepatitis C treatment can be shortened in 50 percent of patients, study finds Eurekalert Inf Dis / 12 November 2018 Access to medicines & diagnostics The Medicines Patent Pool signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir Medicines Patent Pool / 12 November 2018 Life after the cure HCV reinfection uncommon in injection drug users after treatment Healio / 12 November 2018 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive